Migraine Without Aura
Conditions
Brief summary
The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by PACAP compared to patients with few genetic loci associated with migraine (low genetic load).
Detailed description
Migraine is a very prevalent neurological disorder with a strong genetic factor. The common forms of migraine have a multifactorial and polygenic pattern of inheritance and genetics research is crucial for a deeper understanding of migraine mechanisms. Recently, 12 genetic loci have been identified to be associated with migraine with (MA) and without aura (MA) in four large genome-wide association studies (GWAS). The functional consequences of this genetic variant in humans are yet unknown. PACAP is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. PACAP can induce migraine attacks in MO patients via an adenosine monophosphate (cAMP) dependent pathway. Also, a recent study has showed that intracellular accumulation of cAMP is crucial for the induction of migraine attacks. The phenotype of the migraine inducing effects of PACAP might therefore be linked to some of the 12 genetic susceptibility loci that have been identified.
Interventions
DRUGPACAP
Pituitary adenylate cyclase-activating polypeptide (PACAP)
Sponsors
Danish Headache Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Migraine without aura patients genotyped for the 12 newly idetified gene variants associated with migraine.
Exclusion criteria
* Other primary headache * A history of cerebrovascular disease and other CNS- disease * A history suggesting ischaemic heart disease * Serious somatic and mental disease * Hypo- or hypertension * Abuse of alcohol or medicine (opioid analgesics). * Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of migraine attacks induced by PACAP in patients with high and low genetic load. | Change from baseline in headache intensity at 12 hours after the start of infusion of PACAP | The difference in incidence of migraine-like attacks after PACAP between patients with and without high genetic load and patients with low genetic load using verbal rating scale (VRS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of headache induced by PACAP in patients with high and low genetic load. | Change from baseline in headache intensity at 12 hours after the start of infusion of PACAP | The difference in area under the curve (AUC) for headache intensity scores (0-12 hours) after infusion of PACAP |
Countries
Denmark
Outcome results
None listed